Hollis-Eden Pharmaceuticals Announces Appointment of Dr. James M. Frincke President and CEO
15 6월 2009 - 8:05PM
PR Newswire (US)
SAN DIEGO, June 15 /PRNewswire-FirstCall/ -- Hollis-Eden
Pharmaceuticals, Inc. (NASDAQ:HEPH), a leader in the development of
a new class of small molecule compounds based on endogenous adrenal
steroid hormones, today announced the board of directors has
appointed James M. Frincke Ph.D. as President and CEO of
Hollis-Eden Pharmaceuticals, Inc. Dr. Frincke was also elected to
the company's board of directors. Dr. Frincke joined Hollis-Eden as
Vice President, Research and Development in 1997, was promoted to
Executive Vice President in 1999, and to Chief Scientific Officer
in 2001. Dr. Frincke joined Hollis-Eden from Prolinx, Inc., where
he served as Vice President, Therapeutics Research and Development
from 1995 to 1997. During his 28 years in the biotechnology
industry, Dr. Frincke has managed major development programs
including drugs, biologicals, and cellular and gene therapy
products aimed at the treatment of cancer, infectious diseases and
organ transplantation. Since joining the biotechnology industry,
Dr. Frincke has held vice president, research and development
positions in top tier biotechnology companies including
Hybritech/Eli Lilly and SyStemix Inc. (acquired by Novartis). In
various capacities, he has been responsible for all aspects of
pharmaceutical development including early stage research programs,
product evaluation, pharmacology, manufacturing, and the management
of regulatory and clinical matters for lead product opportunities.
Dr. Frincke has authored or co-authored more than 100 scientific
articles, abstracts and regulatory filings. Dr. Frincke received
his B.S. in Chemistry and his Ph.D. in Chemistry from the
University of California, Davis. Dr. Frincke completed his
postdoctoral work at the University of California, San Diego. Dr.
Frincke has been with Hollis-Eden for more than 11 years. About
Hollis-Eden Pharmaceuticals, Inc. Hollis-Eden Pharmaceuticals, Inc.
is developing a new series of small molecule compounds that are
metabolites or synthetic analogs of endogenous hormones derived by
the adrenal glands from the body's most abundant circulating
adrenal steroid. The Company's clinical drug development candidates
include TRIOLEX(R) (HE3286), a next-generation compound currently
in clinical trials for the treatment of type 2 diabetes, ulcerative
colitis and rheumatoid arthritis, and APOPTONE(R) (HE3235), a
next-generation compound in a clinical trial for the treatment of
late-stage prostate cancer. For more information on Hollis-Eden,
visit the Company's website at http://www.holliseden.com/. This
press release contains forward-looking statements within the
meaning of the federal securities laws concerning, among other
things, the potential and prospects of the Company's drug discovery
program and its drug candidates. Any statement included in this
press release that are not a description of historical facts are
forward-looking statements that involve risks, uncertainties,
assumptions and other factors which, if they do not materialize or
prove correct, could cause the Company's actual results to differ
materially from historical results or those expressed or implied by
such forward-looking statements. Such statements are subject to
certain risks and uncertainties inherent in the Company's business,
including, but not limited to: the ability to complete preclinical
and clinical trials successfully and within specified timelines, if
at all; the ability to obtain regulatory approval for TRIOLEX(R)
(HE3286), APOPTONE(R) (HE3235) or any other investigational drug
candidate; the Company's future capital needs; the Company's
ability to obtain additional funding; the ability of the Company to
protect its intellectual property rights and to not infringe the
intellectual property rights of others; the development of
competitive products by other companies; and other risks detailed
from time to time in the Company's filings with the Securities and
Exchange Commission. Existing and prospective investors are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release.
Except as required by law, the Company undertakes no obligation to
update or revise the information contained in this press release as
a result of new information, future events or circumstances arising
after the date of this press release. DATASOURCE: Hollis-Eden
Pharmaceuticals, Inc. CONTACT: Bob Weber, Interim CFO, Hollis-Eden
Pharmaceuticals, Inc., +1-858-587-9333 Web Site:
http://www.holliseden.com/
Copyright
Hollis-Eden Pharmaceuticals (MM) (NASDAQ:HEPH)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Hollis-Eden Pharmaceuticals (MM) (NASDAQ:HEPH)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024